Krystal Biotech, Inc. (NASDAQ:KRYS) Given Average Recommendation of “Moderate Buy” by Brokerages

Krystal Biotech, Inc. (NASDAQ:KRYS) has been given a consensus recommendation of “Moderate Buy” by the eight analysts that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average 12 month price objective among analysts that have issued a report on the stock in the last year is $228.1429.

A number of equities analysts recently commented on KRYS shares. Weiss Ratings reissued a “hold (c+)” rating on shares of Krystal Biotech in a research note on Monday. Chardan Capital boosted their price target on Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Guggenheim set a $224.00 price objective on Krystal Biotech and gave the company a “buy” rating in a research report on Friday, October 17th. Citigroup boosted their target price on shares of Krystal Biotech from $166.00 to $198.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Finally, HC Wainwright restated a “buy” rating and issued a $240.00 price target on shares of Krystal Biotech in a report on Monday, September 15th.

Krystal Biotech Price Performance

NASDAQ:KRYS opened at $238.55 on Wednesday. Krystal Biotech has a 1-year low of $122.80 and a 1-year high of $248.60. The company has a 50-day moving average of $206.32 and a 200 day moving average of $168.63. The firm has a market cap of $6.92 billion, a PE ratio of 35.76 and a beta of 0.48.

Krystal Biotech (NASDAQ:KRYS) last posted its earnings results on Monday, November 3rd. The company reported $2.66 EPS for the quarter, beating analysts’ consensus estimates of $1.12 by $1.54. Krystal Biotech had a net margin of 53.30% and a return on equity of 19.36%. The business had revenue of $97.80 million for the quarter, compared to the consensus estimate of $93.72 million. Sell-side analysts anticipate that Krystal Biotech will post 6.14 EPS for the current fiscal year.

Insiders Place Their Bets

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of Krystal Biotech stock in a transaction on Thursday, December 4th. The shares were sold at an average price of $220.16, for a total value of $5,504,000.00. Following the transaction, the insider directly owned 1,413,711 shares of the company’s stock, valued at approximately $311,242,613.76. The trade was a 1.74% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 13.70% of the stock is currently owned by company insiders.

Institutional Trading of Krystal Biotech

A number of institutional investors have recently made changes to their positions in KRYS. CIBC Bancorp USA Inc. acquired a new position in Krystal Biotech during the 3rd quarter valued at about $467,000. Wilmington Savings Fund Society FSB grew its stake in shares of Krystal Biotech by 78.6% during the third quarter. Wilmington Savings Fund Society FSB now owns 393 shares of the company’s stock worth $69,000 after acquiring an additional 173 shares during the last quarter. Danske Bank A S acquired a new position in shares of Krystal Biotech during the third quarter valued at about $35,000. Advisory Services Network LLC purchased a new position in shares of Krystal Biotech in the 3rd quarter valued at approximately $151,000. Finally, CANADA LIFE ASSURANCE Co boosted its stake in Krystal Biotech by 2.6% in the 3rd quarter. CANADA LIFE ASSURANCE Co now owns 21,398 shares of the company’s stock worth $3,782,000 after purchasing an additional 551 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).